Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450353 | 0.74 | ALDH1A1 (0.42) | LMNAKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL10759266 | 0.73 | CYP2A6 (0.48) | CYP2A6LMNAPIM1KDM4EALDH1A1 | |
| SCHEMBL17714518 | 0.72 | NOTUM (0.41) | KDM4EALDH1A1KMT2A | |
| SCHEMBL20135900 | 0.71 | — | — | |
| SCHEMBL13740175 | 0.70 | TDO2 (0.38) | KDM4EALDH1A1CYP1A2 | |
| SCHEMBL3147551 | 0.69 | — | — | |
| SCHEMBL8066952 | 0.69 | CYP3A4 (0.43) | CYP2A6LMNAALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL586172 | 0.69 | CYP2A6 (0.42) | CYP2A6LMNAPIM1KDM4EALDH1A1 | |
| SCHEMBL9872249 | 0.69 | — | — | |
| SCHEMBL29935805 | 0.67 | CYP2A6 (0.47) | CYP2A6LMNAPIM1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | claimed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | claimed |
| US-9018228-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2427058-B1 | NEMATOCIDAL SULFONAMIDES | DU PONT (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140221203-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735588-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140088309-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-03-27 | — | — | US | disclosed |
| US-8623890-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120114624-A1 | NEMATOCIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2427058-A2 | NEMATOCIDAL SULFONAMIDES | E. I. du Pont de Nemours and Company (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129500-A2 | NEMATOCIDAL SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
| US-5639770-A | SUPEROXIDE INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0600092-A1 | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | CYP2A6 426/4885LMNA 660/4885PIM1 3022/4885 |
| US-20140221203-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | CYP2A6 1382/4885LMNA 3730/4885PIM1 2306/4885 |
| US-20120114624-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | CYP2A6 1382/4885LMNA 3730/4885PIM1 2306/4885 |
| US-20140088309-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | CYP2A6 1382/4885LMNA 3730/4885PIM1 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.